We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Oncimmune Holdings Plc | LSE:ONC | London | Ordinary Share | GB00BYQ94H38 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-1.10 | -4.56% | 23.00 | 22.00 | 24.00 | 25.40 | 25.40 | 25.40 | 37,641 | 16:35:02 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Medical Laboratories | 1.47M | -6.15M | -0.0830 | -3.06 | 18.83M |
TIDMONC
RNS Number : 6216Q
Oncimmune Holdings PLC
30 November 2016
30 November 2016
Oncimmune Holdings plc
("Oncimmune" or the "Company")
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PDMR
Oncimmune Holdings plc (AIM: ONC.L), a leading early cancer detection company developing and commercialising its proprietary EarlyCDT(R) platform technology, today announces that on 30 November 2016, options over ordinary shares of 1 pence each in the capital of the Company ("Ordinary Shares") were awarded to Dan Calvo, President of Oncimmune (USA) LLC, a PDMR, as well as to certain other US staff, under the Company's Oncimmune Holdings Plc Incentive Stock Option Plan (as amended from the Oncimmune Limited Incentive Stock Option Plan that became effective 27 July 2009) as follows:
Name Position Number of Option Interest share options exercise in issued awarded price per share capital share (pence) (%) ----------- ------------------ --------------- --------------- --------------- President of Oncimmune (USA) Dan Calvo LLC 10,151 118.5 0.02 ----------- ------------------ --------------- --------------- ---------------
The options are subject to the rules of the Incentive Stock Option Plan and vest in five equal annual parts, the first fifth vesting on 29 November 2017 and each year thereafter for a further four years, subject to continued employment. The options are exercisable at 118.5 pence, being the mid-market closing price of the Ordinary Shares on 29 November 2016
For further information:
Oncimmune Holdings plc
Geoffrey Hamilton-Fairley, Chief Executive Officer
contact@oncimmune.co.uk
Zeus Capital Limited (Nominated Adviser and Broker)
Phil Walker, Giles Balleny, Dominic Wilson
+44 (0) 203 829 5000
Media enquiries:
Consilium Strategic Communications
Chris Gardner, Mary-Jane Elliott, Matthew Neal, Lindsey Neville
oncimmune@consilium-comms.com
+44 (0) 20 3709 5708
1 Details of the person discharging managerial responsibilities/person closely associated ---- ---------------------------------------------------------------------------------------------------------------- a) Name Dan Calvo ---- ------------------------------------------------------- ------------------------------------------------------- 2 Reason for the notification ---- ---------------------------------------------------------------------------------------------------------------- President of Oncimmune (USA) LLC a) Position/status ---- ------------------------------------------------------- ------------------------------------------------------- b) Initial notification/Amendment Initial Notification ---- ------------------------------------------------------- ------------------------------------------------------- 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor ---- ---------------------------------------------------------------------------------------------------------------- a) Name Oncimmune Holdings plc ---- ------------------------------------------------------- ------------------------------------------------------- b) LEI N/A ---- ------------------------------------------------------- ------------------------------------------------------- 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted ---- ---------------------------------------------------------------------------------------------------------------- a) Description of the financial instrument, type of options over Ordinary Shares - Oncimmune Holdings Plc instrument Incentive Stock Option Plan Identification code ISIN GB00BYQ94H38 ---- ------------------------------------------------------- ------------------------------------------------------- b) Nature of the transaction Grant of options over Ordinary Shares ---- ------------------------------------------------------- ------------------------------------------------------- c) Price(s) and volume(s) Price(s) Volume(s) ---------- ---------- N/A 10,151 ---------- ---------- ---- ------------------------------------------------------- ------------------------------------------------------- d) Aggregated information Price(s) Volume(s) ---------- ---------- N/A 10,151 ---------- ---------- ---- ------------------------------------------------------- ------------------------------------------------------- e) Date of the transaction 30 November 2016 ---- ------------------------------------------------------- ------------------------------------------------------- f) Place of the transaction N/A ---- ------------------------------------------------------- -------------------------------------------------------
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHURSBRNNAAOAA
(END) Dow Jones Newswires
November 30, 2016 12:47 ET (17:47 GMT)
1 Year Oncimmune Chart |
1 Month Oncimmune Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions